Navigation Links
Primary biliary cirrhosis more severe in African-American and Hispanic patients
Date:9/5/2007

Non-Caucasian patients seeking medical care for primary biliary cirrhosis have more severe liver disease compared to Caucasian patients, a new study has found. The reasons for this disparity are not clear, say the authors. These findings are in the September issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

Primary biliary cirrhosis is an uncommon liver disease that typically afflicts Caucasian women between ages 30 and 60, so there is little data available on how it affects non-Caucasian patients. To shed light on this topic, researchers led by Marion Peters of the University of California in San Francisco set out to examine differences in disease severity among patients of various racial and ethnic groups.

They studied 535 individuals with primary biliary cirrhosis who were screened for possible enrollment into a large, national multicenter clinical trial of ursodeoxycholic acid with or without weekly methotrexate, between April, 1989 and January, 1998. For each patient, they collected demographic information, clinical symptoms, physical findings and laboratory test results. They then examined differences between ethnic groups, genders, and anti-mitochondrial antibody (AMA) status. They also compared the 265 patients who entered the trial to those who did not.

The majority of the patients considered for the trial were Caucasian (86.4 percent). Just 7.9 percent were Hispanic, and 3.9 percent were African-American. Still, the researchers noticed significant differences between Caucasian and non-Caucasian patients. Non-Caucasians appeared to have significantly more severe liver disease than Caucasians, as assessed by history, physical examination and laboratory features, the authors report. Minority patients reported more limitation of activity, more severe itching and more serious complications such as ascites, hepatic encephalopathy and variceal bleeding. Results from the laboratory tests confirmed the disparity in disease severity. Mostly as a result of their poorer health conditions, a significantly smaller proportion of non-Caucasian patients were enrolled in the trialjust 23.2 percent compared to 53.5 percent of Caucasians.

The reasons for the health disparities are unknown, since patients in both groups were of similar age and had the disease for similar lengths of time. It is not clear whether these patients have more rapid disease, less access to care early in their disease, misdiagnoses due to inadequate testing, absence of liver biopsies or presence of comorbidities which may have lead to delay in treatment, the authors report.

To begin to address the disparity, they suggest, primary biliary cirrhosis should be considered as the diagnosis in cholestatic liver disease in all ethnic populations.

While the disease does predominantly affect Caucasian women, this study revealed a significant number of racial minority patients, and disturbing evidence of inexplicably more advanced disease.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. Is caries in primary and permanent tooth related?
3. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
4. Shortage Of Funds In Primary Care Trust In UK
5. What Will Primary Care Look Like In England by 2015?
6. Primary Health Care MoU Signed on the Sidelines of the PBD
7. Primary Care centers to provide out patient treatment
8. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
9. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
10. Gene That Causes Metastasis of the Primary Tumor, Identified
11. IMA To Train Doctors In Primary Treatment Of HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... The Magic ... “Consumer’s Choice” Award, for favorite sex toy. Created in collaboration with website Kinkly.com, ... to be consumer voted. The Magic Wand Rechargeable won in stiff competition from ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, ... Bellmore, New York, (516) 784-5858. The office opened earlier this summer and is ... Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical ...
(Date:7/24/2017)... ... ... “A Short Walk to the Mailbox”: a remarkable memoir of an unconventional courtship. ... Ed Clark is a church music director and choral conductor. He has ... worship leader for over fifty years. He has a master’s degree in church ...
(Date:7/23/2017)... ... 2017 , ... Three experts will be interviewed on Facebook ... & Exhibition, to be held in Denver, CO on July 30-August 3, 2017. ... visit the AAPM Facebook page to watch three speakers present their information and ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology: